Eur J Cancer 2011 Nov;47 (17): 2546-51. [IF:4.944]
Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility.
Xiang HP , Geng XP , Ge WW , Li H .
Emergency Department of The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
安徽医科大学附属第二医院急诊科
Abstract
Cell cycle checkpoint kinase 2 (CHEK2) gene has been inconsistently associated with colorectal cancer (CRC), particularly the 1100delC variant. To generate large-scale evidence on whether the CHEK2 1100delC variant is associated with CRC susceptibility we have conducted a meta-analysis. Data were collected from the following electronic databases: PubMed, Excerpta Medica Database and Chinese Biomedical Literature Database, with the last report up to November 2010. The odds ratio (OR) and its 95% confidence interval (95% CI) were used to assess the strength of association. We evaluated the contrast of carriers versus non-carriers. Meta-analysis was performed in a fixed/random effect model by using the software Review Manager 4.2. A total of six studies including 4194 cases and 10,010 controls based on the search criteria were involved in this meta-analysis. A significant association of the CHEK2 1100delC variant with unselected CRC was found (OR=2.11, 95% CI=1.41-3.16, P=0.0003). We also found an association of the CHEK2 1100delC variant with familial CRC (OR=2.80, 95% CI=1.74-4.51, P<0.0001). However, the association was not established for sporadic CRC (OR=1.45, 95% CI=0.49-4.30, P=0.50). This meta-analysis demonstrates that the CHEK2 1100delC variant may be an important CRC-predisposing gene, which increases CRC risk.
摘要：
细胞周期调节激酶CHEK2基因的不一致性，尤其是CHEK2 1100delC的变异，与大肠癌的发生有关。我们对此汇集大量证据进行荟萃分析，来证实CHEK2 1100delC变异是否与大肠癌的易感性有关。我们检索了2010年11月更新的数据库：PubMed, Excerpta Medica Database 和 中国生物医学文献数据库。优势比及其可信区间用来衡量相关性的紧密程度。并且评估了携带者和非携带者之间的差异。应用Review Manager 4.2建立随机效应模型进行荟萃分析。最终纳入了6篇符合标准的研究，包含4194个病例和10010个对照。结果显示，CHEK2 1100delC的变异和非选择性的大肠癌之间呈显著的相关性(OR=2.11, 95% CI=1.41-3.16, P=0.0003)。与此同时，CHEK2 1100delC的变异和家族性大肠癌也有关联(OR=2.80, 95% CI=1.74-4.51, P<0.0001)。然而，CHEK2 1100delC的变异与散发的大肠癌并没有显著相关性(OR=1.45, 95% CI=0.49-4.30, P=0.50)。这项荟萃分析表明，突变的CHEK2 1100delC可能是诱发大肠癌的重要基因，CHEK2 1100delC的变异能够提高患大肠癌的风险。
